[
  {
    "ts": "2025-06-15T09:49:27+00:00",
    "headline": "Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]",
    "url": "https://finance.yahoo.com/news/incyte-incy-targets-1b-growth-094927157.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c9fd403a-ec60-3209-8608-24a559691f4c",
      "content": {
        "id": "c9fd403a-ec60-3209-8608-24a559691f4c",
        "contentType": "STORY",
        "title": "Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches",
        "description": "",
        "summary": "Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]",
        "pubDate": "2025-06-15T09:49:27Z",
        "displayTime": "2025-06-15T09:49:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/e1fa6773f5ef392577533056edd13e16",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NYUC3muJx2iE7TvpUp8AhA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/e1fa6773f5ef392577533056edd13e16.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Aq5oYQ0ynjMTw_jcOpY9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/e1fa6773f5ef392577533056edd13e16.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-targets-1b-growth-094927157.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-targets-1b-growth-094927157.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-15T08:00:00+00:00",
    "headline": "QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)",
    "summary": "VENLO, Netherlands & WILMINGTON, Del., June 15, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibro",
    "url": "https://finance.yahoo.com/news/qiagen-incyte-announce-precision-medicine-080000356.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b7813941-f738-348e-947e-81a854c0ba8b",
      "content": {
        "id": "b7813941-f738-348e-947e-81a854c0ba8b",
        "contentType": "STORY",
        "title": "QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)",
        "description": "",
        "summary": "VENLO, Netherlands & WILMINGTON, Del., June 15, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibro",
        "pubDate": "2025-06-15T08:00:00Z",
        "displayTime": "2025-06-15T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/27fb446ac137251f312cc9d2dd5a2571",
          "originalWidth": 242,
          "originalHeight": 204,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pRxhcheVKjbGwM4l.BaBzA--~B/aD0yMDQ7dz0yNDI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/27fb446ac137251f312cc9d2dd5a2571.cf.webp",
              "width": 242,
              "height": 204,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8pEVgm1zk1igAsA_HyPm.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/27fb446ac137251f312cc9d2dd5a2571.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/qiagen-incyte-announce-precision-medicine-080000356.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/qiagen-incyte-announce-precision-medicine-080000356.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "QGEN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-15T07:15:00+00:00",
    "headline": "Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
    "summary": "WILMINGTON, Del., June 15, 2025--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
    "url": "https://finance.yahoo.com/news/positive-breaking-data-incyte-first-071500578.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "39535379-2f25-38d7-8e54-9221743f6c6b",
      "content": {
        "id": "39535379-2f25-38d7-8e54-9221743f6c6b",
        "contentType": "STORY",
        "title": "Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
        "description": "",
        "summary": "WILMINGTON, Del., June 15, 2025--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
        "pubDate": "2025-06-15T07:15:00Z",
        "displayTime": "2025-06-15T07:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/be3d5f743b3123273d2c2c5df7f0847e",
          "originalWidth": 480,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.UlZ2U5jVnKmVU7BxKYXg--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/be3d5f743b3123273d2c2c5df7f0847e.cf.webp",
              "width": 480,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GfVLjumxmAxThWuzeaqnRQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/be3d5f743b3123273d2c2c5df7f0847e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/positive-breaking-data-incyte-first-071500578.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/positive-breaking-data-incyte-first-071500578.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]